Prodotti competitors / Area Kite, Area Onco-Ema Regulatory news / Area Kite, Area Onco-Ema 3 ottobre 2024 Interius BioTherapeutics receives greenlight from Australian Agency to commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR T for B Cell Malignancies
Normativa europea Regulatory news 2 ottobre 2024 EMA Reflection paper on the use of artificial intelligence in the lifecycle of medicines
Regulatory news Normativa europea 26 settembre 2024 Nuove linee guida dell'OMS propongono raccomandazioni per sperimentazioni cliniche più efficaci ed eque
Prodotti competitors / Area Oncology 24 settembre 2024 Datopotamab deruxtecan: final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Regulatory news Sperimentazione clinica 20 settembre 2024 Improved Search for Clinical Trials in CTIS
Prodotti competitors / Area Oncology 2 settembre 2024 Padcev: EC Decision extension of indication in 1L UC in combination with Keytruda (pembrolizumab)
Prodotti competitors / Area Oncology 29 agosto 2024 Enfortumab vedotin (Padcev) + Pembrolizumab (Keytruda) granted EU approval for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy.
Prodotti competitors / Area Oncology 26 agosto 2024 CHMP Issues Positive Opinion for Astellas' Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer
Prodotti competitors / Area Oncology 26 agosto 2024 Positive CHMP Opinion for Astellas' PADCEV (enfortumab vedotin) in combination with KEYTRUDA® for unresectable or metastatic urothelial cancer
Prodotti competitors / Area Kite, Area Onco-Ema 19 agosto 2024 European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
